Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45

Annals of Neurology

Volumn 77, Issue 4, 2015, Pages 668-674

  Findlay, Andrew R ^a   Wein, Nicolas ^a   Kaminoh, Yuuki ^a   Taylor, Laura E ^a   Dunn, Diane M ^b   Mendell, Jerry R ^a,c   King, Wendy M ^c   Pestronk, Alan ^d   Florence, Julaine M ^d   Mathews, Katherine D ^e   Finkel, Richard S ^f   Swoboda, Kathryn J ^b   Howard, Michael T ^b   Day, John W ^g   McDonald, Craig ^d,h,k   Nicolas, Aurélie ^i,j   Le Rumeur, Elisabeth ^i,j   Weiss, Robert B ^b   Flanigan, Kevin M ^a,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f NEMOURS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITÉ DE RENNES 1   (France)

^j CNRS   (France)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; STEROID;

ADOLESCENT; ADULT; ARTICLE; ASCERTAINMENT BIAS; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHINOPATHY; EXON; EXON SKIPPING; GENE DELETION; GENE MUTATION; HUMAN; IMMOBILIZATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CONFORMATION; SCHOOL CHILD; WHEELCHAIR; YOUNG ADULT; AGED; COHORT ANALYSIS; GENE THERAPY; GENETIC DATABASE; GENETICS; MUSCULAR DYSTROPHY, DUCHENNE; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, GENETIC; EXONS; GENETIC THERAPY; HUMANS; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925456001     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24365     Document Type: Article

References (31)

1. Emery AE,. The muscular dystrophies. Lancet 2002; 359: 687-695.
2. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 2012; 31: 121-125.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2: 90-95.
4. van Deutekom JC, van Ommen GJ,. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 2003; 4: 774-783.
5. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
6. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-1522.
7. Cunniff C, Andrews J, Meaney FJ, et al. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol 2009; 24: 425-430.
8. Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 2009; 30: 934-945.
9. Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009; 30: 1657-1666.
10. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144.
11. Goyenvalle A, Wright J, Babbs A, et al. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther 2012; 20: 1212-1221.
12. Sironi M, Cagliani R, Pozzoli U, et al. The dystrophin gene is alternatively spliced throughout its coding sequence. FEBS Lett 2002; 517: 163-166.
13. Sironi M, Cagliani R, Comi GP, et al. Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles. FEBS Lett 2003; 537: 30-34.
14. Wilton S, Fall A, Harding P, et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007; 15: 1288-1296.
15. van Vliet L, de Winter CL, van Deutekom JC, et al. Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008; 9: 105.
16. Gentil C, Leturcq F, Ben Yaou R, et al. Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation. Hum Mol Genet 2012; 21: 3449-3460.
17. Anthony K, Arechavala-Gomeza V, Ricotti V, et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol 2014; 71: 32-40.
18. Nicolas A, Raguenes-Nicol C, Ben Yaou R, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet. 2014 Oct 27. pii: ddu537. [Epub ahead of print] PubMed PMID: 25348330.
19. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10: 1547-1554.
20. Lo IF, Lai KK, Tong TM, Lam ST,. A different spectrum of DMD gene mutations in local Chinese patients with Duchenne/Becker muscular dystrophy. Chin Med J (Engl) 2006; 119: 1079-1087.
21. Pandey GS, Kesari A, Mukherjee M, et al. Re-evaluation of reading frame-shift hypothesis in Duchenne and Becker muscular dystrophy. Neurol India 2003; 51: 367-369.
22. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991; 49: 54-67.
23. Niemann-Seyde S, Slomski R, Rininsland F, et al. Molecular genetic analysis of 67 patients with Duchenne/Becker muscular dystrophy. Hum Genet 1992; 90: 65-70.
24. Carsana A, Frisso G, Tremolaterra MR, et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. Ann Human Genet 2005; 69 (pt 3): 253-259.
25. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45: 498-506.
26. Takeshima Y, Yagi M, Okizuka Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 2010; 55: 379-388.
27. Todorova A, Todorov T, Georgieva B, et al. MLPA analysis/complete sequencing of the DMD gene in a group of Bulgarian Duchenne/Becker muscular dystrophy patients. Neuromuscul Disord 2008; 18: 667-670.
28. Herczegfalvi A, Toth G, Gyurus P, et al. Deletion patterns of dystrophin gene in Hungarian patients with Duchenne/Becker muscular dystrophies. Neuromuscul Disord 1999; 9: 552-554.
29. Prior TW, Bartolo C, Papp AC, et al. Dystrophin expression in a Duchenne muscular dystrophy patient with a frame shift deletion. Neurology 1997; 48: 486-488.
30. Dwianingsih EK, Malueka RG, Nishida A, et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. J Hum Genet 2014; 59: 423-429.
31. Ruszczak C, Mirza A, Menhart N,. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta 2009; 1794: 921-928.